

ASCO[®]

ASSOCIATION FOR CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

Federal Regulatory and Legislative Policy

Shimere Williams Sherwood, PhD
Director, Science and Research Policy

May 2023

DISCLOSURES


I have no financial disclosures, financial relationships, or conflicts of interest.

ASCO and State Affiliates: Partners in Advocacy

- Sign-on letters to Congress
 - Meetings with federal & state policymakers
 - Grassroots alerts
 - Social media campaigns
 - Joint state letters
 - Testimony at state hearings
 - Regulatory comments
-




Landscape on Capitol Hill



Senate
51 Ds* - 49 Rs

*Includes three Independents



House of Representatives
213 Ds - 222 Rs

118th Congress: ASCO's Priorities

Medicare Physician Payment

Prior Authorization

Pharmacy Benefit Managers


Cancer Research Funding

Other Ongoing Priorities

Medicare Physician Payment

2023 Focus

- Long-term reform needed
- Educating lawmakers
- Urging Congress to hold hearings
- APM bonus expires at year end



Prior Authorization

Multi-pronged advocacy approach

- Proposed rules
- Federal legislation
- State legislation
- Survey & new position statement
- Ad campaigns
- Social media



Pharmacy Benefit Managers (PBMs)

Advocating at all levels

- Capitol Hill
 - Bipartisan, bicameral attention
 - Multiple bills
- Legislation across the states
- Regulatory activity
- Investigations



Fiscal Year 2024 Appropriations

	FY 2022 – Enacted	FY 2023 – Enacted	FY 2024 – Asks
NIH	\$44.959 billion	\$47.459 billion	\$50.924 billion
NCI	\$6.913 billion	\$7.32 billion*	\$9.988 billion
ARPA-H	\$1 billion	\$1.5 billion	At least \$1.5 billion

*2023 is the last year of funding for the original Cancer Moonshot

ARPA-H

- New Federal Agency
 - High-risk, transformative research
 - Ambitious mid- and long-term projects
 - Disease specific vs. Broadly applicable
- New Leadership
 - Renee Wegrzyn, PhD
 - Program Managers (3-5yr)
 - \$1B until Sept. 30, 2024
- Stakeholders Expectations
 - Hire outside civil service
 - Complement NIH Research
 - Broad, flexible, separate funding
 - Stakeholder engagement
 - Health equity and diversity



Cancer Moonshot(S)

- Administration - “Phase II” of the Cancer Moonshot
- Last year of current Cancer Moonshot funding
- New Goals
 1. Speed progress of cutting-edge research through the pipeline
 2. Better understand and address environmental exposures
 3. Increase screenings and the types of screenings
 4. Improve patients, survivors, and their caregivers experience and learn from each of them
 5. Address inequities in access to care and treatment, including clinical trials
- Phase II – 7-year funding or longer?
- Congressional Action??

Overarching Goals:

- ❖ Reduce the death rate from cancer by at least 50% over the next 25 years
- ❖ Improve the experience of people & their families living with & surviving cancer
- ❖ End cancer as we know it today

Quote Permission Granted: On Moonshots and Space Rocks, ASCO Morning Rounds, CEO Reflections, Oct. 3, 2022.

National Cancer Plan

- Dr. Bertagnolli described ambitious plan—continued emphasis on breaking molds to innovate/streamline
 - Doubling clinical trial enrollment
 - Increasing diversity, special focus on older participants
- Moonshot and NCP -“All of Government” approach, not just NCI

National Cancer Plan

8 Goals:

1. Prevent Cancer
2. Detect Cancers Early
3. Develop Effective Treatments
4. Eliminate Inequities
5. Deliver Optimal Care
6. Engage Every Person
7. Maximize Data Utility
8. Optimize the Workforce

Other Policy Issues to Watch

- ✓ Drug Shortages
- ✓ VALID Act
- ✓ Oral Parity
- ✓ Pediatric Cancer
- ✓ Tobacco/ENDS
- ✓ PHE Unwinding
- ✓ Open Access



- ✓ Drug Pricing
- ✓ Step Therapy
- ✓ Copay Accumulators
- ✓ Telemedicine
- ✓ Clinical Trials Diversity
- ✓ Patient Centric Trials
- ✓ Cancer Screening

ASCO Advocacy: Get Involved

ASCO[®] ACT Network

- Action alerts with ASCO positions on key bills
- Provides draft messages to personalize & send to your lawmakers
- Visit www.asco.org/ACTNetwork

Advocacy at Home

- Meet with your lawmakers in the state or district

